Carvana (CVNA) Exceeds Market Returns: Some Facts to Consider — Neutral
CVNA Zacks Investment Research — February 10, 2025Carvana (CVNA) concluded the recent trading session at $267.81, signifying a +1.42% move from its prior day's close.

VALE S.A. (VALE) Rises Higher Than Market: Key Facts — Neutral
VALE Zacks Investment Research — February 10, 2025In the most recent trading session, VALE S.A. (VALE) closed at $9.56, indicating a +0.95% shift from the previous trading day.

CRH (CRH) Stock Dips While Market Gains: Key Facts — Neutral
CRH Zacks Investment Research — February 10, 2025CRH (CRH) closed at $102.07 in the latest trading session, marking a -1.23% move from the prior day.

BigBear.ai Holdings, Inc. (BBAI) Laps the Stock Market: Here's Why — Neutral
BBAI Zacks Investment Research — February 10, 2025In the most recent trading session, BigBear.ai Holdings, Inc. (BBAI) closed at $8.72, indicating a +1.51% shift from the previous trading day.

Gladstone Commercial (GOOD) Stock Sinks As Market Gains: Here's Why — Negative
GOOD Zacks Investment Research — February 10, 2025In the latest trading session, Gladstone Commercial (GOOD) closed at $16.14, marking a -0.55% move from the previous day.

Dick's Sporting Goods (DKS) Rises Higher Than Market: Key Facts — Neutral
DKS Zacks Investment Research — February 10, 2025In the most recent trading session, Dick's Sporting Goods (DKS) closed at $236.65, indicating a +1.18% shift from the previous trading day.

Hyster-Yale (HY) Beats Stock Market Upswing: What Investors Need to Know — Positive
HY Zacks Investment Research — February 10, 2025In the closing of the recent trading day, Hyster-Yale (HY) stood at $52.60, denoting a +0.9% change from the preceding trading day.

Louisiana-Pacific (LPX) Stock Declines While Market Improves: Some Information for Investors — Neutral
LPX Zacks Investment Research — February 10, 2025Louisiana-Pacific (LPX) closed at $114.51 in the latest trading session, marking a -0.62% move from the prior day.

Southern Co. (SO) Laps the Stock Market: Here's Why — Neutral
SO Zacks Investment Research — February 10, 2025The latest trading day saw Southern Co. (SO) settling at $85.51, representing a +1.1% change from its previous close.

Western Midstream (WES) Rises Yet Lags Behind Market: Some Facts Worth Knowing — Negative
WES Zacks Investment Research — February 10, 2025Western Midstream (WES) closed the most recent trading day at $40.57, moving +0.47% from the previous trading session.

Star Bulk Carriers (SBLK) Laps the Stock Market: Here's Why — Neutral
SBLK Zacks Investment Research — February 10, 2025In the most recent trading session, Star Bulk Carriers (SBLK) closed at $15.66, indicating a +1.82% shift from the previous trading day.

GO Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges GO Investors with Losses to Contact the Firm — Neutral
GO PRNewsWire — February 10, 2025RADNOR, Pa. , Feb. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Grocery Outlet Holding Corp. ("Grocery Outlet") (NASDAQ: GO) on behalf of those who purchased or acquired Grocery Outlet securities between November 7, 2023, and May 7, 2024, inclusive (the "Class Period").

Kilroy Realty (KRC) Surpasses Q4 FFO and Revenue Estimates — Positive
KRC Zacks Investment Research — February 10, 2025Kilroy Realty (KRC) came out with quarterly funds from operations (FFO) of $1.20 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to FFO of $1.08 per share a year ago.

Here's What Key Metrics Tell Us About Arch Capital (ACGL) Q4 Earnings — Neutral
ACGL Zacks Investment Research — February 10, 2025While the top- and bottom-line numbers for Arch Capital (ACGL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Apollo Commerical Finance (ARI) Reports Q4 Earnings: What Key Metrics Have to Say — Positive
ARI Zacks Investment Research — February 10, 2025Although the revenue and EPS for Apollo Commerical Finance (ARI) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Brixmor (BRX) Reports Q4 Earnings: What Key Metrics Have to Say — Positive
BRX Zacks Investment Research — February 10, 2025Although the revenue and EPS for Brixmor (BRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, PennantPark (PFLT) Q1 Earnings: A Look at Key Metrics — Positive
PFLT Zacks Investment Research — February 10, 2025The headline numbers for PennantPark (PFLT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

PennantPark (PNNT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates — Positive
PNNT Zacks Investment Research — February 10, 2025Although the revenue and EPS for PennantPark (PNNT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Analog Devices (ADI) Stock Sinks As Market Gains: Here's Why — Negative
ADI Zacks Investment Research — February 10, 2025Analog Devices (ADI) reachead $204.86 at the closing of the latest trading day, reflecting a -0.17% change compared to its last close.

Investors who Lost Money on Pliant Therapeutics, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - PLRX — Neutral
PLRX Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
